Celcuity (CELC), a clinical stage biotech focused on targeted cancer therapies, has caught investor attention after recent share price moves. This has prompted a closer look at how its fundamentals line up with current market expectations.

Recent moves in Celcuity’s share price look like an extension of a strong run, with a 1-day share price return of 8.23% adding to a 30-day share price return of 11.48% and a very large 1-year total shareholder return. Together, these point to building momentum at a current share price of $134.72.

If Celcuity’s surge has you curious about other high growth themes in healthcare, this could be a good moment to scan 34 healthcare AI stocks

With Celcuity now trading at $134.72, a value score of 2, an intrinsic discount figure and a market cap of about $6.0b, the key question is simple: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 15.4% Overvalued

Celcuity's most followed narrative pegs fair value at $116.70, compared with the last close at $134.72, which sets up a clear valuation gap to unpack.

Management estimates a US$5b to US$6b addressable market in second line HR positive, HER2 negative advanced breast cancer and has indicated potential peak revenue for gedatolisib of US$2.5b to US$3b in this setting. If partially realized, this would be a key driver of top line growth over time.

Want to see what kind of revenue ramp and profit profile would need to sit behind that valuation gap? The narrative leans on aggressive top line expansion, a step change in margins and a future earnings multiple more typical of mature market leaders rather than early commercial biotechs.

Result: Fair Value of $116.70 (OVERVALUED)

However, this story can quickly change if key trials for gedatolisib disappoint or if regulators delay approvals, which could stretch Celcuity’s current losses and funding runway.

Another View: DCF Points the Other Way

So far, the analyst narrative suggests Celcuity looks about 15.4% overvalued against a fair value of $116.70. Our DCF model lands in a very different place, with a future cash flow value of $760.43, which implies the current $134.72 price is trading at a very large discount. Which story do you trust more: analyst targets or long term cash flow math?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celcuity for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With both bullish and cautious signals on the table, this is a good time to review the numbers yourself, decide where you stand, and then weigh up the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If Celcuity is already on your radar, do not stop there. The next step is lining up a few more high conviction ideas that fit your style.

• Target quality at a discount by scanning 47 high quality undervalued stocks that combine solid fundamentals with prices that sit below their assessed worth.
• Strengthen your income stream by checking 13 dividend fortresses built around higher yielding companies with consistent payout records.
• Reduce portfolio stress by reviewing 67 resilient stocks with low risk scores that score well on resilience and financial stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.